Mavacamten in Patients with Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 56 Results from the VALOR-HCM Randomized Clinical Trial

Milind Y. Desai*, Anjali Owens, Kathy Wolski, Jeffrey B. Geske, Sara Saberi, Andrew Wang, Mark Sherrid, Paul C. Cremer, Neal K. Lakdawala, Albree Tower-Rader, David Fermin, Srihari S. Naidu, Nicholas G. Smedira, Hartzell Schaff, Ellen McErlean, Christina Sewell, Lana Mudarris, Zhiqun Gong, Kathy Lampl, Amy J. SehnertSteven E. Nissen

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

66 Scopus citations

Fingerprint

Dive into the research topics of 'Mavacamten in Patients with Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 56 Results from the VALOR-HCM Randomized Clinical Trial'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science

Neuroscience